Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1422142/000156459017023441/arpo-10q_20170930.htm
SEC Filings
ARPO Annual Reports
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
ARPO Quarterly Reports
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
ARPO Corporate News
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales August 2021
Financial Exhibit
New Agreement August 2021
Vote of Security Holders August 2021
Earnings Release
Financial Exhibit August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders July 2021
Financial Exhibit
Regulated Disclosure June 2021
Earnings Release
Financial Exhibit May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales May 2021
Event for Officers
Financial Exhibit April 2021
Earnings Release
Financial Exhibit March 2021
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
August 2021
Financial Exhibit
New Agreement
New Agreement
August 2021
Vote of Security Holders
August 2021
Earnings Release
Financial Exhibit
Financial Exhibit
August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
July 2021
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
June 2021
Earnings Release
Financial Exhibit
Financial Exhibit
May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
May 2021
Event for Officers
Financial Exhibit
Financial Exhibit
April 2021
Earnings Release
Financial Exhibit
Financial Exhibit
March 2021
Last10K.com | 10-Q Quarterly Report Mon Nov 13 2017
Exhibit 99.1
Aerpio Reports First Quarter 2017 Financial Results
May 16, 2017 08:00 AM Eastern Daylight Time
CINCINNATI—(BUSINESS WIRE) — Aerpio Pharmaceuticals, Inc. (“the Company”), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2017.
“In the first quarter, we announced our $40 million private placement and completed our reverse merger transaction,” said Joseph H. Gardner, CEO of Aerpio. “This new capital enables us to further the development of our product candidates, including the initiation of our planned Phase 2b clinical trial of AKB-9778 in patients with moderate to severe diabetic retinopathy. We look forward to the progress of this trial.”
Financial Highlights
As of March 31, 2017, the Company had cash and cash equivalents and short term investments of $35.2 million, compared to $1.6 million as of December 31, 2016. During the three months ended March 31, 2017, the Company received net proceeds of $37.2 million from the previously announced March 2017 financing as well as $0.3 million in January from an extension to the Aerpio senior secured convertible note financing in March 2016.
The following table summarizes our results of operations for the periods presented:
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Operating expenses: |
||||||||
| Research and development |
$ | 2,255,584 | $ | 2,989,558 | ||||
| General and administrative |
2,504,001 | 1,215,885 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
4,759,585 | 4,205,443 | ||||||
|
|
|
|
|
|||||
| Operating loss |
(4,759,585 | ) | (4,205,443 | ) | ||||
| Grant income |
35,657 | 8,670 | ||||||
| Interest (expense) income, net |
(271,775 | ) | 1,078 | |||||
| Other income, net |
— | 997 | ||||||
|
|
|
|
|
|||||
| Total other (expense) income, net |
(236,118 | ) | 10,745 | |||||
|
|
|
|
|
|||||
| Net loss and comprehensive loss |
$ | (4,995,703 | ) | $ | (4,194,698 | ) | ||
|
|
|
|
|
|||||
The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Tuesday, May 16, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aerpio Pharmaceuticals, Inc..
Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets (parenthetical) (unaudited)
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Loss (unaudited)
Condensed Consolidated Statements Of Stockholders Equity (deficit)
Condensed Consolidated Statements Of Stockholders Equity (deficit) (parenthetical)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (details)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Schedule Of Future Payments Related To Operating Leases (detail)
Common Stock
Common Stock - Additional Information (detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (detail)
Income Taxes
Income Taxes - Additional Information (detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (detail)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (tables)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Computation Of Basic And Diluted Net Loss Per Share (detail)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Weighted Average Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Notes Payable To Investors
Notes Payable To Investors - Additional Information (detail)
Preferred Stock
Preferred Stock - Additional Information (detail)
Related-party Arrangements
Related-party Arrangements (tables)
Related-party Arrangements - Summary Of Activities Included In Statements Of Operations And Comprehensive Loss (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Stock Options Valuation Assumptions (detail)
Stock-based Compensation - Summary Of Recognized Compensation Cost Related To Employee And Non-employee Stock-based Compensation Activity (detail)
Stock-based Compensation - Summary Of Restricted Stock Activity (detail)
Stock-based Compensation - Summary Of Stock Option Activity (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Schedule Of Assets Measured On Recurring Basis (detail)
Material Contracts, Statements, Certifications & more
Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ARPO
CIK: 1422142
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-17-023441
Submitted to the SEC: Mon Nov 13 2017 9:26:38 AM EST
Accepted by the SEC: Mon Nov 13 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/arpo/0001564590-17-023441.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...